A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Attig, Sebastian ^a   Price, Leah ^b   Janetzki, Sylvia ^c   Kalos, Michael ^d   Pride, Michael ^e   McNeil, Lisa ^e   Clay, Tim ^f   Yuan, Jianda ^g   Odunsi, Kunle ^h   Hoos, Axel ⁱ   Romero, Pedro ^j   Britten, Cedrik M ^a,k  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b NEW YORK UNIVERSITY   (United States)

^c ZellNet Consulting Inc   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e PFIZER INC   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h ROSWELL PARK CANCER INSTITUTE   (United States)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j UNIVERSITY OF LAUSANNE   (Switzerland)

^k BIONTECH AG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HLA ANTIGEN; COLORING AGENT; PEPTIDE;

ACCURACY; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL VIABILITY; CLINICAL PROTOCOL; CONTROLLED STUDY; FLOW CYTOMETRY; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNODETECTION; PRACTICE GUIDELINE; PROTEIN BINDING; PROTEIN MULTIMERIZATION; QUALITY CONTROL; REPRODUCIBILITY; STAINING; BIOLOGY; CELL FRACTIONATION; CELL SURVIVAL; CYTOLOGY; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; METHODOLOGY;

BIOLOGICAL MARKERS; CD8-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; COLORING AGENTS; COMPUTATIONAL BIOLOGY; HLA ANTIGENS; HUMANS; LYMPHOCYTE COUNT; PEPTIDES; PROTEIN BINDING; PROTEIN MULTIMERIZATION; REPRODUCIBILITY OF RESULTS; STAINING AND LABELING; SUBCELLULAR FRACTIONS;

EID: 79960033714     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-108     Document Type: Article

References (19)

1. Schloot NC, Meierhoff G, Karlsson FM, Ott P, Putnam A, Lehmann P, et al. Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the third immunology of diabetes society T-cell workshop. J Autoimmun 2003, 21:365-376. 10.1016/S0896-8411(03)00111-2, 14624759.
2. Cox JH, Ferrari G, Kalams SA, Lopaczynski W, Oden N, D'souza MP. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses 2005, 21:68-81. 10.1089/aid.2005.21.68, 15665646.
3. Janetzki S, Cox JH, Oden N, Ferrari G. Standardization and validation issues of the ELISPOT assay. Methods Mol Biol 2005, 302:51-86.
4. Maecker HT, Rinfret A, D'Souza P, Darden J, Roig E, Landry C, et al. Standardization of cytokine flow cytometry assays. BMC Immunol 2005, 6:13.
5. Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C, Hoos A. Toward the harmonization of immune monitoring in clinical trials: Quo vadis?. Cancer Immunol Immunother 2007, 57:285-288. 10.1007/s00262-007-0379-z, 2150641, 17721782.
6. Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, et al. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 2008, 57:303-315. 10.1007/s00262-007-0380-6, 2150634, 17721781.
7. Britten CM, Janetzki S, Ben Porat L, Clay TM, Kalos M, Maecker H, et al. Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother 2009, 58:1701-1713. 10.1007/s00262-009-0681-z, 2714899, 19259668.
8. Smith SG, Joosten SA, Verscheure V, Pathan AA, McShane H, Ottenhoff TH, et al. Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis. PLoS One 2009, 4:e7972. 10.1371/journal.pone.0007972, 2776358, 19956718.
9. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996, 274:94-96. 10.1126/science.274.5284.94, 8810254.
10. Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, et al. "MIATA"-minimal information about T cell assays. Immunity 2009, 31:527-528. 10.1016/j.immuni.2009.09.007, 19833080.
11. Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, et al. Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother 2010, 60:15-22. 10.1007/s00262-010-0940-z, 3029829, 21080166.
12. Smith JG, Joseph HR, Green T, Field JA, Wooters M, Kaufhold RM, et al. Establishing acceptance criteria for cell-mediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions. Clin Vaccine Immunol 2007, 14:527-537. 10.1128/CVI.00435-06, 1865640, 17376862.
13. Roederer M. How many events is enough? Are you positive?. Cytometry A 2008, 73:384-385.
14. Coulie PG, van der Bruggen P. T-cell responses of vaccinated cancer patients. Curr Opin Immunol 2003, 15:131-137. 10.1016/S0952-7915(03)00009-8, 12633661.
15. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006, 24:175-208. 10.1146/annurev.immunol.24.021605.090733, 16551247.
16. Boddy L, Wilkins MF, Morris CW. Pattern recognition in flow cytometry. Cytometry 2001, 44:195-209. 10.1002/1097-0320(20010701)44:3<195::AID-CYTO1112>3.0.CO;2-H, 11429770.
17. Chan C, Feng F, Ottinger J, Foster D, West M, Kepler TB. Statistical mixture modeling for cell subtype identification in flow cytometry. Cytometry A 2008, 73:693-701. 2840702, 18496851.
18. Boedigheimer MJ, Ferbas J. Mixture modeling approach to flow cytometry data. Cytometry A 2008, 73:421-429.
19. Frelinger J, Ottinger J, Gouttefangeas C, Chan C. Modeling flow cytometry data for cancer vaccine immune monitoring. Cancer Immunol Immunother 2010, 59:1435-1441. 10.1007/s00262-010-0883-4, 2892609, 20563720.